Editorial: Picking the Right Patient for Human Epidermal Growth Factor Receptor 3–Targeted Therapy in Platinum-Resistant Ovarian Cancer Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, December 22, 2016

Editorial: Picking the Right Patient for Human Epidermal Growth Factor Receptor 3–Targeted Therapy in Platinum-Resistant Ovarian Cancer



JCO editorial


In conclusion, we congratulate Liu et al8 for not only conducting
a well-designed trial but also having the foresight to collect
the biospecimens necessary to conduct a rigorous biomarker
evaluation. Their efforts have identified a potential path forward
for this drug in ovarian cancer, salvaging what otherwise would
have been a negative study
. Moving forward, it is critical that we
follow in the example of Liu et al and ensure that we have the
opportunity to learn from our failures to ultimately improve the
outcome for our patients.

In the article that accompanies this editorial, Liu et al8 report
the results of a 233-patient open-label, randomized phase II trial of
once-weekly paclitaxel with or without the human epidermal growth
factor receptor 3 (HER3) antibody, seribantumab, in platinum resistant/
refractory epithelial ovarian cancer. Patients were randomly
assigned 2:1 in favor of seribantumab and enrolled without
prospective biomarker selection or stratification.....

original article:
 Liu JF, Ray-Coquard I, Selle F, et al: Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum resistant or -refractory ovarian cancer. J Clin Oncol 34:4345-4353, 2016

0 comments :

Post a Comment

Your comments?